After positions at Novartis and Merck, Bettina Bauer, a trained scientist, joined Gilead in 2019 as VP and general manager of its German affiliate.…

Based at Gilead Sciences' Hong Kong hub, as VP & GM of Asia, Turkey, and the Middle East, American Dustin Haines oversees a vast region that…

16-year Gilead veteran, Vítor Papão, recently left Europe to take on a new role within the company as general manager of the vast Middle East &…

The third and final piece in Lenias Hwenda of Medicines for Africa's series looking back at the challenges and successes of HIV/AIDS treatments over…

The second in a three-part series looking back at the challenges and successes of HIV/AIDS treatments over the past 40 years and potential medical…

In the first of a series looking back at the challenges and successes of HIV/AIDS treatments over the past 40 years and potential medical…

While HIV has shifted from a death sentence to a manageable disease in most developed nations, there are several reasons why it still represents a…

The Access to Medicine Index, a biennial report that gauges the efforts of the world’s largest pharma companies to expand access in low- and…

In only 21 years, the Global Fund has made remarkable progress in the fight to eliminate HIV, tuberculosis (TB), and malaria across the world,…

With several COVID-19 vaccines gaining regulatory approval across the world in record time, a spotlight has been shone on the vaccines field more…

Christian Probst gives an overview of GSK Norway’s broad portfolio, market access hurdles, and the importance of bringing clinical trials back to…

Dr Johan Van Hoof, global therapeutic area head of vaccines for Janssen, shares his extensive career experience in vaccines; the learnings from…